Therapeutic | Urelumab |
Target | TNFRSF9 |
Heavy Chain | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK |
100% seqID Fv Structure | 6mhr [Fvs: AB, DE] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6mhr [Fvs: AB, DE] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Medarex UltiMAb Mouse |
INN Year Proposed | 2010 |
INN Year Recommended | 2011 |
Companies Involved | Bristol-Myers Squibb, National Cancer Institute (USA), Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Chicago, Medarex |
Conditions Approved | na |
Conditions Active | Non-Hodgkin's lymphoma, Solid tumours, Glioblastoma, Multiple myeloma |
Conditions Discontinued | Colorectal cancer, Head and neck cancer, Malignant melanoma, Non-small cell lung cancer |
Notes | Jain paper: "VL sequence modified at one position to match patent document (US7659384) and JK germline" |